THIS TRIAL IS NO LONGER RECRUITING PATIENTS.

The following requirements are mandatory for patients interested in participating in Therion's PROSTVAC-VF Phase II study:

1. Male patients >= 18 years of age;

2. Evidence of metastatic disease including either of the following:
a. Lymph node metastasis measurable by CT and/or;
b. bone metastasis evaluable by bone scan;

3. Refractory to hormone therapy defined by: evidence of two consecutive increases in PSA documented over a previous reference value, the first occurring a minimum of 1 week from the reference value, with one value of at least 5 ng/mL;

4. Castrate testosterone levels < 50 ng/dL consistent with orchiectomy or continuous treatment with GnRH agonists for the duration of the study;

5. Gleason Score <= 7 (at initial diagnosis).

Patients with any of the below conditions are not eligible to participate in Therion's PROSTVAC-VF Phase II study:

1. Concurrent or prior biologic therapy or immunotherapy for cancer;

2. Concurrent therapy such as palliative radiation or opioid analgesics for tumor-associated pain;

3. Radiation therapy within 28 days prior to registration;

4. Antiandrogen therapy or any other hormone therapy within 42 days of registration;

5. Prior chemotherapy for prostate cancer;

6. Metastasis to organ systems other than lymph nodes and bone;

7. Hypersensitivity to eggs or egg products;

8. Prior or concurrent extensive eczema or acute, chronic, or exfoliative skin disorders (e.g., extensive psoriasis, burns, impetigo, or disseminated zoster, varicella zoster, severe acne, or other open rashes or wounds).